Inflammation, Immunity, and Vaccine Development for the Gastric Pathogen Helicobacter pylori

  • Tamaki Ikuse
  • Thomas G. BlanchardEmail author
  • Steven J. Czinn
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 421)


It has been over 30 years since a link was established between H. pylori infection of the gastric mucosa and the development of chronic gastric diseases. Research in rodent models supported by data from human tissue demonstrated that the host immune response to H. pylori is limited by host regulatory T cells. Immunization has been shown to induce a potent Th1- and Th17-mediated immune response capable of eradicating or at least significantly reducing the bacterial load of H. pylori in the stomach in small animal models. These results have not translated well to humans. Clinical trials employing many of the strategies used in rodents for oral immunization including the use of a mucosal adjuvant such as Escherichia coli LT or delivery by attenuated enteric bacteria have failed to limit H. pylori infection and have highlighted the potential toxicity of exotoxin-based mucosal adjuvants. A recent study, however, utilizing a recombinant fusion protein of H. pylori urease and the subunit B of E. coli LT, was performed on over 4000 children. Efficacy of over 70% was demonstrated against naturally acquired infection compared to control volunteers one year post-immunization. Efficacy was reduced, but still above 50% at three years. This study provided new insight into the strategies for developing an improved vaccine for widespread use in countries with high infection rates and where gastric cancer (GC) remains one of the most common causes of death due to cancer.


Helicobacter Vaccine Adjuvant IL-17 Immunity 


  1. Aebischer T, Bumann D, Epple HJ, Metzger W, Schneider T, Cherepnev G et al (2008) Correlation of T cell response and bacterial clearance in human volunteers challenged with Helicobacter pylori revealed by randomised controlled vaccination with Ty21a-based Salmonella vaccines. Gut 57(8):1065–1072. Scholar
  2. Arakawa T, Yu J, Chong DK, Hough J, Engen PC, Langridge WH (1998) A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 16(10):934–938. Scholar
  3. Arnold IC, Dehzad N, Reuter S, Martin H, Becher B, Taube C et al (2011a) Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest 121(8):3088–3093. Scholar
  4. Arnold IC, Lee JY, Amieva MR, Roers A, Flavell RA, Sparwasser T et al (2011b) Tolerance rather than immunity protects from Helicobacter pylori-induced gastric preneoplasia. Gastroenterology 140(1):199–209. Scholar
  5. Bamford KB, Fan X, Crowe SE, Leary JF, Gourley WK, Luthra GK et al (1998) Lymphocytes in the human gastric mucosa during Helicobacter pylori have a T helper cell 1 phenotype. Gastroenterology 114(3):482–492CrossRefGoogle Scholar
  6. Banerjee S, Medina-Fatimi A, Nichols R, Tendler D, Michetti M, Simon J et al (2002) Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 51(5):634–640CrossRefGoogle Scholar
  7. Bergerot I, Ploix C, Petersen J, Moulin V, Rask C, Fabien N et al (1997) A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci U S A 94(9):4610–4614CrossRefGoogle Scholar
  8. Bimczok D, Clements RH, Waites KB, Novak L, Eckhoff DE, Mannon PJ et al (2010) Human primary gastric dendritic cells induce a Th1 response to H. pylori. Mucosal Immunol 3(3):260–269. Scholar
  9. Blanchard TG, Czinn SJ (2017) Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer disease. Pediatr Res 81(1–2):170–176. Scholar
  10. Blanchard TG, Czinn SJ, Redline RW, Sigmund N, Harriman G, Nedrud JG (1999) Antibody-independent protective mucosal immunity to gastric Helicobacter infection in mice. Cell Immunol 191(1):74–80. Scholar
  11. Blanchard TG, Lycke N, Czinn SJ, Nedrud JG (1998) Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis. Immunology 94(1):22–27CrossRefGoogle Scholar
  12. Blanchard TG, Nedrud JG (2010) Helicobacter pylori vaccines. In: Sutton P and Mitchell H (eds) Helicobacter pylori in the 21st century, vol 17. CABI, Wallingford, UK, pp 167–189Google Scholar
  13. Blaser MJ, Chen Y, Reibman J (2008) Does Helicobacter pylori protect against asthma and allergy? Gut 57(5):561–567. Scholar
  14. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F et al (2009) A review of human carcinogens–Part B: biological agents. Lancet Oncol 10(4):321–322CrossRefGoogle Scholar
  15. Chen M, Lee A, Hazell S (1992) Immunisation against gastric Helicobacter infection in a mouse/Helicobacter felis model. Lancet 339(8801):1120–1121CrossRefGoogle Scholar
  16. Chen Y, Blaser MJ (2007) Inverse associations of Helicobacter pylori with asthma and allergy. Arch Intern Med 167(8):821–827. Scholar
  17. Chen Y, Blaser MJ (2008) Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis 198(4):553–560. Scholar
  18. Corthesy-Theulaz I, Porta N, Glauser M, Saraga E, Vaney AC, Haas R et al (1995) Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 109(1):115–121CrossRefGoogle Scholar
  19. Cuenca R, Blanchard TG, Czinn SJ, Nedrud JG, Monath TP, Lee CK et al (1996) Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets. Gastroenterology 110(6):1770–1775CrossRefGoogle Scholar
  20. Czinn SJ, Cai A, Nedrud JG (1993) Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine 11(6):637–642CrossRefGoogle Scholar
  21. Czinn SJ, Nedrud JG (1991) Oral immunization against Helicobacter pylori. Infect Immun 59(7):2359–2363PubMedPubMedCentralGoogle Scholar
  22. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D et al (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13(6):607–615. Scholar
  23. D’Elios MM, Manghetti M, De Carli M, Costa F, Baldari CT, Burroni D et al (1997) T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J Immunol 158(2):962–967PubMedGoogle Scholar
  24. Dellon ES, Peery AF, Shaheen NJ, Morgan DR, Hurrell JM, Lash RH et al (2011) Inverse association of esophageal eosinophilia with Helicobacter pylori based on analysis of a US pathology database. Gastroenterology 141(5):1586–1592. Scholar
  25. DeLyria ES, Redline RW, Blanchard TG (2009) Vaccination of mice against H. pylori induces a strong Th-17 response and immunity that is neutrophil dependent. Gastroenterology 136(1):247–256. Scholar
  26. den Hollander WJ, Sonnenschein-van der Voort AM, Holster IL, de Jongste JC, Jaddoe VW, Hofman A et al (2016) Helicobacter pylori in children with asthmatic conditions at school age, and their mothers. Aliment Pharmacol Ther 43(8):933–943. Scholar
  27. Doidge C, Crust I, Lee A, Buck F, Hazell S, Manne U (1994) Therapeutic immunisation against Helicobacter infection. Lancet 343(8902):914–915CrossRefGoogle Scholar
  28. Eaton KA, Mefford M, Thevenot T (2001) The role of T cell subsets and cytokines in the pathogenesis of Helicobacter pylori gastritis in mice. J Immunol 166(12):7456–7461CrossRefGoogle Scholar
  29. Elson CO, Ealding W (1984) Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 132(6):2736–2741PubMedGoogle Scholar
  30. Engler DB, Reuter S, van Wijck Y, Urban S, Kyburz A, Maxeiner J et al (2014) Effective treatment of allergic airway inflammation with Helicobacter pylori immunomodulators requires BATF3-dependent dendritic cells and IL-10. Proc Natl Acad Sci U S A 111(32):11810–11815. Scholar
  31. Ermak TH, Giannasca PJ, Nichols R, Myers GA, Nedrud J, Weltzin R et al (1998) Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med 188(12):2277–2288CrossRefGoogle Scholar
  32. Feldman RA, Eccersley AJ, Hardie JM (1998) Epidemiology of Helicobacter pylori: acquisition, transmission, population prevalence and disease-to-infection ratio. Br Med Bull 54(1):39–53CrossRefGoogle Scholar
  33. Ferrero RL, Thiberge JM, Kansau I, Wuscher N, Huerre M, Labigne A (1995) The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci U S A 92(14):6499–6503CrossRefGoogle Scholar
  34. Fischbach LA, Nordenstedt H, Kramer JR, Gandhi S, Dick-Onuoha S, Lewis A et al (2012) The association between Barrett’s esophagus and Helicobacter pylori infection: a meta-analysis. Helicobacter 17(3):163–175. Scholar
  35. Fox JG, Correa P, Taylor NS, Lee A, Otto G, Murphy JC et al (1990) Helicobacter mustelae-associated gastritis in ferrets. An animal model of Helicobacter pylori gastritis in humans. Gastroenterology 99(2):352–361CrossRefGoogle Scholar
  36. Graham DY, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, Adam E (1991) Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 100(6):1495–1501CrossRefGoogle Scholar
  37. Graham DY, Opekun AR, Osato MS, El-Zimaity HM, Lee CK, Yamaoka Y et al (2004) Challenge model for Helicobacter pylori infection in human volunteers. Gut 53(9):1235–1243. Scholar
  38. Guo L, Yin R, Xu G, Gong X, Chang Z, Hong D et al (2017) Immunologic properties and therapeutic efficacy of a multivalent epitope-based vaccine against four Helicobacter pylori adhesins (urease, Lpp20, HpaA, and CagL) in Mongolian gerbils. Helicobacter 22(6).
  39. Harris PR, Wright SW, Serrano C, Riera F, Duarte I, Torres J et al (2008) Helicobacter pylori gastritis in children is associated with a regulatory T-cell response. Gastroenterology 134(2):491–499. Scholar
  40. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S et al (2011) Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 20(3):299–304PubMedGoogle Scholar
  41. IARC (2012) Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 100(Pt B):1–441Google Scholar
  42. Ito M, Takata S, Tatsugami M, Wada Y, Imagawa S, Matsumoto Y et al (2009) Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review. J Gastroenterol 44(5):365–371. Scholar
  43. Kato M, Asaka M, Ono S, Nakagawa M, Nakagawa S, Shimizu Y et al (2007) Eradication of Helicobacter pylori for primary gastric cancer and secondary gastric cancer after endoscopic mucosal resection. J Gastroenterol 42(Suppl 17):16–20. Scholar
  44. Koch KN, Hartung ML, Urban S, Kyburz A, Bahlmann AS, Lind J, Backert S, Taube C, Müller A (2015) Helicobacter urease-induced activation of the TLR2/NLRP3/IL-18 axis protects against asthma. J Clin Invest 125:3297–3302. Scholar
  45. Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi S et al (2007) Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 45(12):4006–4010. Scholar
  46. Kotloff KL, Sztein MB, Wasserman SS, Losonsky GA, DiLorenzo SC, Walker RI (2001) Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 69(6):3581–3590. Scholar
  47. Lee A, Buck F (1996) Vaccination and mucosal responses to Helicobacter pylori infection. Aliment Pharmacol Ther 10(Suppl 1):129–138CrossRefGoogle Scholar
  48. Lee A, Fox JG, Otto G, Murphy J (1990) A small animal model of human Helicobacter pylori active chronic gastritis. Gastroenterology 99(5):1315–1323CrossRefGoogle Scholar
  49. Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS et al (2016) Association between Helicobacter pylori eradication and gastric cancer incidence: A systematic review and meta-analysis. Gastroenterology 150(5):1113–1124.e1115. Scholar
  50. Li B, Chen L, Sun H, Yang W, Hu J, He Y et al (2015) Immunodominant epitope-specific Th1 but not Th17 responses mediate protection against Helicobacter pylori infection following UreB vaccination of BALB/c mice. Sci Rep 5:14793. Scholar
  51. Lindholm C, Quiding-Jarbrink M, Lonroth H, Hamlet A, Svennerholm AM (1998) Local cytokine response in Helicobacter pylori-infected subjects. Infect Immun 66(12):5964–5971PubMedPubMedCentralGoogle Scholar
  52. Liu W, Tan Z, Xue J, Luo W, Song H, Lv X et al (2016) Therapeutic efficacy of oral immunization with a non-genetically modified Lactococcus lactis-based vaccine CUE-GEM induces local immunity against Helicobacter pylori infection. Appl Microbiol Biotechnol 100(14):6219–6229. Scholar
  53. Luther J, Dave M, Higgins PD, Kao JY (2010) Association between Helicobacter pylori infection and inflammatory bowel disease: a meta-analysis and systematic review of the literature. Inflamm Bowel Dis 16(6):1077–1084. Scholar
  54. Lycke N, Holmgren J (1986) Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 59(2):301–308PubMedPubMedCentralGoogle Scholar
  55. Lycke N, Karlsson U, Sjolander A, Magnusson KE (1991) The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand J Immunol 33(6):691–698CrossRefGoogle Scholar
  56. Lycke N, Tsuji T, Holmgren J (1992) The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol 22(9):2277–2281. Scholar
  57. Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF et al (2012) Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 104(6):488–492. Scholar
  58. Mabe K, Takahashi M, Oizumi H, Tsukuma H, Shibata A, Fukase K et al (2009) Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? World J Gastroenterol 15(34):4290–4297CrossRefGoogle Scholar
  59. Mahboubi M, Falsafi T, Sadeghizadeh M, Mahjoub F (2017) The role of outer inflammatory protein A (OipA) in vaccination of theC57BL/6 mouse model infected by Helicobacter pylori. Turk J Med Sci 47(1):326–333. Scholar
  60. Maldonado RA, von Andrian UH (2010) How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 108:111–165. Scholar
  61. Malfertheiner P, Selgrad M, Wex T, Romi B, Borgogni E, Spensieri F, et al (2018) Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study. Lancet Gastroenterol Hepatol
  62. Matsumoto Y, Blanchard TG, Drakes ML, Basu M, Redline RW, Levine AD et al (2005) Eradication of Helicobacter pylori and resolution of gastritis in the gastric mucosa of IL-10-deficient mice. Helicobacter 10(5):407–415. Scholar
  63. Michetti P, Corthesy-Theulaz I, Davin C, Haas R, Vaney AC, Heitz M et al (1994) Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology 107(4):1002–1011CrossRefGoogle Scholar
  64. Michetti P, Kreiss C, Kotloff KL, Porta N, Blanco JL, Bachmann D et al (1999) Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 116(4):804–812CrossRefGoogle Scholar
  65. Mizuno T, Ando T, Nobata K, Tsuzuki T, Maeda O, Watanabe O et al (2005) Interleukin-17 levels in Helicobacter pylori-infected gastric mucosa and pathologic sequelae of colonization. World J Gastroenterol 11(40):6305–6311CrossRefGoogle Scholar
  66. Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M (2016) Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 65(9):1439–1446. Scholar
  67. Nedrud JG, Liang XP, Hague N, Lamm ME (1987) Combined oral/nasal immunization protects mice from Sendai virus infection. J Immunol 139(10):3484–3492PubMedGoogle Scholar
  68. NIH Consensus Conference (1994) Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 272:65–69CrossRefGoogle Scholar
  69. Nishizawa T, Maekawa T, Watanabe N, Harada N, Hosoda Y, Yoshinaga M et al (2015) Clarithromycin versus metronidazole as first-line Helicobacter pylori eradication: a multicenter, prospective, randomized controlled study in Japan. J Clin Gastroenterol 49(6):468–471. Scholar
  70. Oertli M, Muller A (2012) Helicobacter pylori targets dendritic cells to induce immune tolerance, promote persistence and confer protection against allergic asthma. Gut Microbes 3(6):566–571. Scholar
  71. Oertli M, Noben M, Engler DB, Semper RP, Reuter S, Maxeiner J et al (2013) Helicobacter pylori gamma-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci U S A 110(8):3047–3052. Scholar
  72. Oertli M, Sundquist M, Hitzler I, Engler DB, Arnold IC, Reuter S et al (2012) DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J Clin Invest 122(3):1082–1096. Scholar
  73. Parkin DM (2004) International variation. Oncogene 23(38):6329–6340. Scholar
  74. Petersen JS, Bregenholt S, Apostolopolous V, Homann D, Wolfe T, Hughes A et al (2003) Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes. Clin Exp Immunol 134(1):38–45CrossRefGoogle Scholar
  75. Ploix C, Bergerot I, Durand A, Czerkinsky C, Holmgren J, Thivolet C (1999) Oral administration of cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing CD4+ regulatory T-cells. Diabetes 48(11):2150–2156CrossRefGoogle Scholar
  76. Posselt G, Backert S, Wessler S (2013) The functional interplay of Helicobacter pylori factors with gastric epithelial cells induces a multi-step process in pathogenesis. Cell Commun Signal 11:77. Scholar
  77. Reibman J, Marmor M, Filner J, Fernandez-Beros ME, Rogers L, Perez-Perez GI et al (2008) Asthma is inversely associated with Helicobacter pylori status in an urban population. PLoS ONE 3(12):e4060. Scholar
  78. Robinson K, Kenefeck R, Pidgeon EL, Shakib S, Patel S, Polson RJ et al (2008) Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut 57(10):1375–1385. Scholar
  79. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G (2007) Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 5(12):1413–1417.
  80. Rolig AS, Carter JE, Ottemann KM (2011) Bacterial chemotaxis modulates host cell apoptosis to establish a T-helper cell, type 17 (Th17)-dominant immune response in Helicobacter pylori infection. Proc Natl Acad Sci U S A 108(49):19749–19754. Scholar
  81. Rubenstein JH, Inadomi JM, Scheiman J, Schoenfeld P, Appelman H, Zhang M et al (2014) Association between Helicobacter pylori and Barrett’s esophagus, erosive esophagitis, and gastroesophageal reflux symptoms. Clin Gastroenterol Hepatol 12(2):239–245. Scholar
  82. Rupnow MFT, Chang AH, Shachter RD, Owens DK, Parsonnet J (2009) Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J Infect Dis 200(8):1311–1317. Scholar
  83. Shi Y, Liu XF, Zhuang Y, Zhang JY, Liu T, Yin Z et al (2010) Helicobacter pylori-induced Th17 responses modulate Th1 cell responses, benefit bacterial growth, and contribute to pathology in mice. J Immunol 184(9):5121–5129. Scholar
  84. Shimizu T, Haruna H, Ohtsuka Y, Kaneko K, Gupta R, Yamashiro Y (2004) Cytokines in the gastric mucosa of children with Helicobacter pylori infection. Acta Paediatr 93(3):322–326CrossRefGoogle Scholar
  85. Sonnenberg A, Lash RH, Genta RM (2010) A national study of Helicobactor pylori infection in gastric biopsy specimens. Gastroenterology 139(6):1894–1901.
  86. Sougioultzis S, Lee CK, Alsahli M, Banerjee S, Cadoz M, Schrader R et al (2002) Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine 21(3–4):194–201CrossRefGoogle Scholar
  87. Spangler BD (1992) Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev 56(4):622–647PubMedPubMedCentralGoogle Scholar
  88. Stoicov C, Fan X, Liu JH, Bowen G, Whary M, Kurt-Jones E et al (2009) T-bet knockout prevents Helicobacter felis-induced gastric cancer. J Immunol 183(1):642–649. Scholar
  89. Sun H, Yuan H, Tan R, Li B, Guo G, Zhang J et al (2018) Immunodominant antigens that induce Th1 and Th17 responses protect mice against Helicobacter pylori infection. Oncotarget 9(15):12050–12063. Scholar
  90. Sun JB, Holmgren J, Czerkinsky C (1994) Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci U S A 91(23):10795–10799CrossRefGoogle Scholar
  91. Sun JB, Rask C, Olsson T, Holmgren J, Czerkinsky C (1996) Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci U S A 93(14):7196–7201CrossRefGoogle Scholar
  92. Sutton P, Boag JM (2018) Status of vaccine research and development for Helicobacter pylori. Vaccine.
  93. Take S, Mizuno M, Ishiki K, Hamada F, Yoshida T, Yokota K et al (2015) Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer; a prospective cohort study. J Gastroenterol 50(6):638–644. Scholar
  94. Vajdy M, Lycke NY (1992) Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunology 75(3):488–492PubMedPubMedCentralGoogle Scholar
  95. Wang Q, Yu C, Sun Y (2013) The association between asthma and Helicobacter pylori: a meta-analysis. Helicobacter 18(1):41–53. Scholar
  96. Wang YC, Lin TY, Shang ST, Chen HJ, Kao CH, Wu CC et al (2017) Helicobacter pylori infection increases the risk of adult-onset asthma: a nationwide cohort study. Eur J Clin Microbiol Infect Dis 36(9):1587–1594. Scholar
  97. Yamaoka Y, Kato M, Asaka M (2008) Geographic differences in gastric cancer incidence can be explained by differences between Helicobacter pylori strains. Intern Med 47(12):1077–1083CrossRefGoogle Scholar
  98. Zeng M, Mao XH, Li JX, Tong WD, Wang B, Zhang YJ et al (2015) Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 386(10002):1457–1464. Scholar
  99. Zhou X, Wu J, Zhang G (2013) Association between Helicobacter pylori and asthma: a meta-analysis. Eur J Gastroenterol Hepatol 25(4):460–468. Scholar
  100. Zhuang Y, Shi Y, Liu XF, Zhang JY, Liu T, Fan X et al (2011) Helicobacter pylori-infected macrophages induce Th17 cell differentiation. Immunobiology 216(1–2):200–207. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Tamaki Ikuse
    • 1
  • Thomas G. Blanchard
    • 2
    Email author
  • Steven J. Czinn
    • 2
  1. 1.Department of Pediatric and Adolescent MedicineJuntendo University Graduate School of MedicineTokyoJapan
  2. 2.Department of PediatricsUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations